| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2803162901011 | 316290101 | TRUXIMA C/S.SOL.IN 500MG/VIAL BTx1 VIAL x50 ML | 793.58 | 805.48 | 905.04 |
| 05/2018 | 2803162902018 | 316290201 | TRUXIMA C/S.SOL.IN 100MG/10ML VIAL (10MG/ML) BTx2 VIALS x10 ML | 248.02 | 251.75 | 298.88 |
For treatment of CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.
The Fab regions of rituximab binds to the CD20 antigen on B lymphocytes, while the Fc domain recruits antibodies and complements to mediate cell lysis.
0.8 hours (mammalian reticulocytes, in vitro)
* 3.1 L
* 0.34 L/day [RA patients]